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ANATOMY, PHYSIOLOGY AND MANAGEMENT OF PATIENTS WITH
DIFFUSE PULMONARY ARTERIOVENOUS MALFORMATIONS
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Malformation Center, Yale University School of Medicine, New Haven, CT; 2
Department of Respiratory Medicine, Policlinic of Bari, Bari, Italy.

Diffuse pulmonary vascular malformations (PAVMs) are a small and understudied, but
nevertheless important subset of the PAVM population of patients, associated with significant
mortality and morbidity.
A review of literature was undertaken to investigate the current understanding of diffuse
PAVMs. This review demonstrated that no additional attempts to define diffuse PAVMs and describe
their natural history was made before or after the in 2000 report by Faughnan et al {{51
Faughnan,M.E. 2000; }}.
To further expand the findings from 2000, we performed a retrospective review of 36 patients
(21 female, 15 male) with diffuse PAVMs from a cohort of 821 consecutive patients with PAVMs.
Diffuse PAVMs were classified angiographically as involving one or more segmental pulmonary
arteries in one or both lungs. The following data were noted from the chart review: Hereditary
Hemorrhagic Telangiectasia (HHT) status, gender, age at presentation, presence or absence of large
focal PAVMs, oxygen saturations, morbidity and mortality.
Twenty nine out of 36 (81%) patients had HHT. Diffuse PAVMs were more commonly
bilateral 26/36 (72%) than unilateral 10/36 (28%) (p=0.02). Initial O2 saturations of patients with
unilateral and bilateral diffuse PAVM were 87% ± 7% and 79% ± 8% (p=0.02), which the current
values are 95% ± 3% and 85% ± 7% (p < .0001) respectively. Nine deaths occurred, but only in
patients with bilateral involvement. Deaths were due to hemoptysis from bronchial artery hypertrophy
(2), brain hemorrhage (1) and abscess (1), spontaneous liver necrosis (3), operative death during
attempted lung transplantation (1), and hemorrhage from duodenal ulcer (1).
Yearly follow-up is recommended for this group of patients as they are at high risk for
complications.
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INTRODUCTION
Hereditary Hemorrhagic Telangiectasia (HHT), also know as Osler-Weber-Rendu
syndrome is a clinically and genetically diverse multisystemic vascular disorder (1). The
manifestations of HHT are a result of abnormal vasculature, characterized by lack of
capillary networks resulting in direct arteriovenous connections and fragile dilated
vessels of various sizes. Telangiectases are small vascular lesions found on the face, lips,
hands, as well as oral, nasal and GI mucosa(1). Arteriovenous malformations (AVMs) are
larger vascular lesions found most commonly in the lung (2), brain(3), liver (4) , or GI
tract(5), and less commonly spinal cord(6).
HHT is a condition with an equal gender distribution, affecting all races and ethnic
groups worldwide. The prevalence of HHT appears to be more common than previously
thought. The reported incidence rates vary from country to country, and are found to be
anywhere from 1 in 2351 in the French region of Ain (7), 1 in 3500 on the Danish island
of Funen (8), 1 in 5155 in the Leeward Islands (9), 1 in 5,000-8,000 in the region of Akita
in Japan (10), 1 in 16,500 in Vermont (11), and 1 in 39,216 in northern England (12). The
general lack of public and physician awareness about HHT makes it a highly underdiagnosed condition.
HHT was first recognized toward the end of the 19th century as a genetic disorder
causing nosebleeds, GI bleeding, and abnormal vascular structures. The first known
report describing what is now known as hereditary hemorrhagic telangiectasia dates back
to 1864 from Sutton’s report of epistaxis as a result of degeneration of the vascular
system (13). In 1896, Rendu distinguished the disease from hemophilia, and reported the
association of epistaxis, cutaneous telangiectasia, and familial occurrence (14). A number
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of case reports followed, including those by Osler (15)and Weber (16) further describing
the disorder. These resulted in the eponym Osler-Weber-Rendu syndrome. However, the
often preferred term “hereditary hemorrhagic telangiectasia” was coined in 1909 by
Hanes (17), as an acknowledgement of the three features that defined the disorder at the
time.
Currently, the clinical diagnosis of HHT is established according to the Curaçao
criteria, as described by Shovlin et al (18), where fulfillment of three out of the four
criteria is required for a definite clinical diagnosis of HHT:
1. spontaneous recurrent nosebleeds (epistaxis)
2. mucocutaneous telangiectases
3. visceral AVMs
4. positive family history
If only two criteria are present, the diagnosis of HHT is possible or suspected, and if less
than two are present, the diagnosis is unlikely.

Genetics
HHT is a genetically heterogeneous autosomal dominant disorder with incomplete
penetrance and age-related expressivity. Lethality of the homozygous condition is
generally accepted, given the studies demonstrating lethality of homozygous ENG and
ALK1 knockout mice, which die in the embryonic stage at mid-gestation, as well as the
absence of conclusive reports on living homozygous individuals (19).
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Five genotypes have been identified to date in HHT patients (Figure 1). The two
main types of HHT, type 1 and type 2, are caused by mutations is the following genes,
respectively:
1. ENG - localized on chromosome 9, encodes endoglin, a type III TGF-β receptor
(20)
2.

ALK-1 - localized on chromosome 12, encodes the activin receptor-like kinase 1,
a type I TGF-β receptor (21).
Recently, mutations were identified in several other genes: SMAD 4 - a gene

localized on chromosome 18, in families with both HHT and juvenile polyposis (22), as
well as two unidentified genes- on chromosome 5 (HHT 3) (23) and chromosome 7
(HHT 4) (24).
Several studies investigating the prevalence of ENG and ALK-1 mutations in HHT
have shown conflicting results (25-28). The most recent study investigating this topic
included the largest series of patients reported to date and has shown predominance of
ALK-1 over ENG mutations (29).
Currently, genetic testing for HHT is available on a clinical basis for mutations in
endoglin and ALK-1. Genetic testing for SMAD 4 is only available as a research test, and
will be soon available clinically. A study by Cohen et al (30) has recently shown that
genetic screening with targeted clinical protocol is more economically attractive than the
conventional clinical screening, resulting in a reduction in the number of clinical tests for
family members who do not have HHT. Therefore, once an individual with HHT is
identified, screening and genetic counseling should be offered to the family.
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Pathogenesis
The corresponding ENG and ALK-1 proteins are specific endothelial receptors of
the TGF-β superfamily essential for maintaining vascular integrity (19). Generally, type
II TGF-ß receptors or accessory proteins (ENG) bind the ligand, subsequently forming a
complex with type I receptors (ALK-1), which then activate downstream cytoplasmic
signaling molecules including SMADs. SMADs translocate to the nucleus and modulate
gene transcription(31). Therefore, it is expected that the abnormal vessels in HHT
develop because of aberrant TGF-ß signaling at some stage during vascular development
and homeostasis.
It has been shown that endothelial cells derived from HHT1 or HHT2 patients
express approximately one half of the normal endoglin or ALK-1 levels, respectively(32,
33), and that endothelial cells derived directly from AVMs also express half the normal
levels of endoglin(34). Therefore, the current understanding is that HHT results from
endoglin or ALK-1 haploinsufficiency (lack of sufficient protein for normal function),
rather than from a “second hit” (additional local loss of endoglin expression). A
complicated series of processes seems to be involved in the development and remodeling
of blood vessels, and in addition to genetic factors, environmental factors might play an
important role. Present knowledge about the function of endoglin and ALK1 in
endothelial cells and the current haploinsufficiency model have suggested that the future
therapeutic perspectives for HHT might include an increased expression of either
endoglin or ALK1 (19). However, as the exact pathogenesis of HHT continues to be only
speculative, it is still early to consider gene therapy as a treatment or prevention option.
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Genotype-Phenotype Correlations
Significant clinical variability is observed in HHT, with both intra- and interfamilial variations in age-of-onset, localization of lesions, and severity of complications.
Genotype-phenotype correlations have been studied, but are still limited.
HHT type 1:
•

earlier onset of epistaxis (35)

•

higher number of PAVMs (35-37)

•

higher number of CNS vascular malformations(35, 38)

HHT type 2:
•

increased incidence of hepatic AVMs (35, 39, 40)

•

reduced penetrance, lower expressivity, and a later age-of-onset (41)

All manifestations of HHT have been reported in both types, with the exception of
rare reports of primary pulmonary hypertension (42, 43) and spinal AVMs (35), which
have only been reported in HHT2.
The frequency of mucocutaneous telangiectases in different age groups appears to be
similar in patients with either HHT1 or HHT2. By age 40, multiple telangiectases in one
or more of the characteristic locations (hands, face, mouth) are found in 100% patients
(35).
Furthermore, the predominance of HHT1 or HHT2 is thought to correlate with
geographical location. While HHT1 is predominant in North America, Canada and
Northern Europe, HHT2 is more abundant in the Mediterranean countries such as Italy,
Spain and France (19).
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Women and HHT
Women seem to be at an increased risk of developing PAVMs, as well as possibly
hepatic involvement and cerebral hemorrhage (44). This may reflect a modification of the
HHT vasculature by female hormones, as well as hemodynamic changes during
pregnancy. These hormonal effects have been supported by the successful treatment of
gastrointestinal bleeding in HHT patients using combined estrogen-progesterone
therapy(45), a report of progesterone receptors in vessels of HHT patients (46), and
variations in epistaxis during the menstrual cycle and menopause(47).

Clinical Manifestations of HHT
Manifestations of HHT are generally not present at birth, rather they develop with
increasing age. An important exception are cerebral AVMs which have been described as
early as during the neonatal period, representing a significant cause of mortality and
morbidity in children with HHT (48, 49). Epistaxis is usually the earliest manifestation of
disease, often occurring in childhood, pulmonary AVMs becoming apparent from
puberty, with mucocutaneous and gastrointestinal telangiectases developing progressively
with age.

Epistaxis
The most common manifestation of HHT is recurrent epistaxis, a result of the
fragility and subsequent spontaneous bleeding from nasal mucosal telangiectases(1).
While some patients only have occasional nosebleeds, others experience significant
bleeding on a daily basis. Many patients require no treatment other than iron
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supplementation, whereas others may require transfusions and emergency nasal packing.
A number of topical, systemic, and surgical treatments are available for the treatment of
epistaxis in HHT, but the principle of “doing as little as possible for as long as possible”
seems to be the best, except in cases of HHT patients experiencing massive hemorrhage
or daily nose bleeds (31).

Skin
Mucocutaneous telangiectases occur in about 75% of individuals occurring mostly
on the face, lips, tongue and buccal mucosa, as well as fingertips (50). They typically
present later in life than epistaxis, from about the second or third decade of life,
increasing in size and number with age (50). They may bleed but this is rarely clinically
important and the main concern is cosmetic, when short term benefits of laser or other
ablation therapies may be obtained(31).

GI tract
Recurrent gastrointestinal tract hemorrhage occurs in about 25-33% of HHT
patients, with a late onset, usually from the fifth or sixth decade (5, 50), and may result in
severe anemia and blood transfusion requirements. Anemia out of proportion to epistaxis
is often a presenting sign of GI hemorrhage (5). Distinguishing between epistaxis and GI
bleeding can be challenging, given that many HHT patients are placed on iron
supplementation that causes dark stools, making it difficult to detect a GI bleed. Epistaxis
can also mimic GI bleeding upon swallowing of nasal blood (5). The extent of
telangiectases, which are most commonly found in the stomach, duodenum and jejunum,
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was found to correlate with the severity of a patient’s anemia and transfusion requirement
(5).
Treatment of HHT-related GI bleeding can be challenging. Most patients are
managed conservatively with oral iron supplementation and, if necessary, blood
transfusions. Other therapies include lasers and cautery, as well as various
pharmacologic agents. The only pharmacologic therapy supported by randomized
controlled trials is the use of female hormones in heavily transfusion-dependent
patients.(45). Others include danazol (a weak androgen) and aminocaproic acid (inhibits
fibrinolysis), both only supported by case reports (51-53). Risks and benefits should be
carefully weighed in the decision to use drug therapy, taking into account the number of
telangiectases and severity of bleeding versus potential side effects of treatment (5). If
present, PAVMs should be repaired before initiation of hormonal therapy. Endoscopic
treatment of asymptomatic telangiectases is not warranted, and surveillance endoscopy is
unlikely to benefit patients if they show an improvement with treatment (5).

Liver
Although the majority of patients with HHT have hepatic vascular malformations,
symptoms occur in only a minority, around the age of 30, and with clear female gender
predominance (54). The symptoms of liver involvement in HHT are associated with
blood shunting (arteriovenous, arterioportal, or portovenous), and fall into one of three
categories: high output heart failure, portal hypertension, or biliary disease (4).
A clinical suspicion of hepatic involvement should be raised in an HHT patient with
shortness of breath and/or edema without PAVMs or anemia, or those with ascites,
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variceal hemorrhage, abdominal pain, encephalopathy or cholangitis. In either case, a
physical examination finding of a bruit or thrill in the RUQ or epigastrium supports the
diagnosis (54). Hepatomegaly and/or abnormal liver function tests may be present, as
well.
A definite diagnosis of liver involvement is made with various imaging studies,
including angiography (4), computed tomography (55) , MRI (56), or Doppler
sonography (57). According to consensus recommendations from the HHT Scientific
Meeting in Lyon in April 2005(58), Doppler ultrasound is sufficiently accurate and
should be the first-line imaging of the liver in the general HHT population, but only in
those in whom liver involvement is suspected. Liver biopsy in any patient with HHT is
considered unnecessary and should be avoided (58). According to the same consensus
recommendations, liver transplantation should only be considered after failure of
intensive medical therapy, and embolization of liver vascular malformations is a high-risk
procedure and should only be used as a last resort in patients who are not candidates for
liver transplantation.

Brain
Brain malformations in HHT include mainly telangiectases and cerebral AVMs
(CAVMs). Most complications arise from CAVMs, which are thought to affect more than
10% of HHT patients(3, 31). They can lead to headache, seizures, ischemia of the
surrounding tissue due to a steal effect, or hemorrhage. CAVMs can cause symptoms as
early as during the neonatal period. In 2002, the first neonatal case of intracranial
hemorrhage (ICH) secondary to a CAVM was reported in a patient who was
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subsequently found to have HHT (48). In addition, the same group reported 8 more
infants and children, ages 4 weeks to 16 years, who also presented with ICH secondary to
CAVMs. Before these hemorrhages, none of the children were suspected of having HHT,
despite a family history of the disease, demonstrating that infants and children with a
family history of HHT are at risk for sudden and catastrophic ICH. Another study of
arteriovenous fistulas (AVFs) in 41 children, demonstrated that even though cerebral
AVFs are a rare disease, they are not infrequently seen in neonates and infants with
AVMs, and that HHT is suspected to be present in about one fourth of these patients (49).
Therefore, screening for CAVMs (Figure 2) with a single baseline MRI may potentially
identify and prevent more serious sequelae (59). Neurovascular surgery, embolization
and stereotactic radiosurgery may be used to treat CAVMs (1).
It is important to note that neurological symptoms occur not only due to cerebral or
spinal AVMs, but also even more commonly with pulmonary AVMs. PAVMs can lead to
cerebral abscess (9%) or TIA/stroke (24%) due to right-to-left shunting that facilitates the
passage of paradoxical emboli into the cerebral circulation. But, the most common
neurological manifestation of PAVMs is migraines (43%) (60). Several hypotheses have
been formulated in explaining the increased prevalence of migraines in patients with
PAVMs (61). A causal relationship between the presence of a right-to-left shunt and
migraines has been suggested, and supported by a study which demonstrated a decreased
prevalence of migraines in HHT patients that underwent embolization of PAVMs(62).
Trigger substances, such as serotonin or micro emboli, instead of being trapped in the
pulmonary capillaries might enter the systemic circulation via the shunt, resulting in
cerebral vascular instability and causing migraine (63).
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Lung
Together with the brain AVMs, pulmonary AVMs are the greatest cause of
mortality and morbidity in HHT patients. It is not surprising then that the lung is the best
studied organ involved in HHT to date. PAVMs are a marker for HHT, since about 8590% of people with PAVMs have HHT (2). PAVMs are present in about 30% of patients
with HHT, although the incidence varies depending on the specific genetic mutation
present (64). PAVMs are more common in females, which may relate to effects of female
hormones on HHT vasculature (44).
PAVMs are dilated, thin-walled vessels that replace normal capillaries between the
pulmonary artery and vein (65). The presence of this high-flow low-resistance circuit
gives rise to right-to-left shunting of deoxygenated blood, resulting in hypoxemia, and
manifesting as clubbing, cyanosis and dyspnea. Orthodeoxia, a further decrease in
oxygen saturation on assuming an upright posture, is common in HHT patients with
PAVMs, and is attributed to increased flow of blood under the influence of gravity
through shunts situated at the lung bases (44).
The loss of filtering capacity provided by pulmonary capillaries produces a conduit
through which paradoxical emboli can pass into the systemic circulation, causing
catastrophic neurological complications such as stroke and cerebral abscess. Neurological
sequelae occur in about 40% of adults with untreated PAVMs, with approximately 30%
of patients having a history of stroke, and 10% of brain abscess. Hemorrhagic
complications include pulmonary or pleural hemorrhage and hemoptysis, and occur in
about 10-15% of HHT patients with PAVMs(60, 66).
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The angioarchitecture of PAVMs has been extensively studied in adults (2, 60, 67,
68). PAVMs are classified as focal (95%) or diffuse (5%) (67, 69). Focal PAVMs were
further classified as simple (90%) or complex (10%)(2). A PAVM is considered simple
when it is fed by one or more branches from the same pulmonary segmental artery. If
more than one segmental artery is involved, the PAVM is considered complex. As
originally characterized by Faughnan et al in 2000 (69), diffuse PAVMs are defined as
involving all segmental arteries of at least one lobe of the lung. These patients are usually
deeply cyanotic and have a greater predisposition to neurological complications.
The presence (but not size, location or number) of PAVMs is detected with high
sensitivity and specificity using contrast echocardiography (CE), which is accompanied
by injection of agitated saline solution. In normal individuals, all the microbubbles
formed are filtered out by the pulmonary capillaries, and none should appear in the left
side of the heart. In the presence of an intracardiac shunt (e.g. PFO, ASD or VSD),
bubbles will appear in left cardiac chambers almost immediately after filling the right
heart chambers. If there is a shunt at the pulmonary level (e.g. PAVM), bubbles will be
seen in left cardiac chambers 2-3 cardiac cycles after filling the right heart chambers (64).
A significant proportion of patients, presumably those with PAVMs that are too small,
will have shunting identified on echocardiography, but not on CT or even pulmonary
angiography (44). These patients are still advised to use antibiotic prophylaxis and
follow-up CT scanning on the assumption that PAVMs are present (Figure 3).
Together with pulse oximetry (considered positive if oxygen saturation < 97%), CE
has replaced shunt studies and non-contrast CT as initial screening methods. If either CE
or pulse oximetry are positive, thin section non-contrast CT is used to determine the size
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and type of PAVMs, which are included in the treatment criteria. In children,
measurement of supine and upright oxygen saturation can be used for screening for
PAVMs, with CE generally used after the age of 12, or earlier in cases when pulse
oximetry is low, growth failure or difficulty with physical activity are present (70). In
addition, exercise testing is currently being developed at Yale as an alternate screening
method for PAVMs in children, in which a drop in oxygen saturation on exercise is
indicative of the presence of significant PAVMs.
Before 1980, surgery was the only method of treatment; ligation, local excision,
segmentectomy, lobectomy, or pneumonectomy was performed in most cases (2).
Surgical resection may still have a role in patients in whom right-to-left shunting persists
after embolization of all feasible vessels (44), or if a patient has severe contrast allergy,
precluding angiography. Embolization therapy, first described by Porstmann in 1977
occludes the feeding arteries to a PAVM (71). Treatment using transcatheter
embolotherapy (TCE) can prevent many of the debilitating and life-threatening
complications of simple and complex type PAVMs, such as exercise intolerance due to
hypoxemia, prevention of neurological complications and prevention of lung hemorrhage
(2). TCE is a safe and efficient non-surgical procedure, which avoids major surgery,
general anesthesia, and loss of pulmonary parenchyma. It is currently recommended for
all pulmonary AVMs with a feeding artery 3 mm (60, 68, 72). The procedure is
technically successful in over 98% of cases (71). Outcomes in children are as successful
as in adults, with similar complication rates (70). Long-term follow-up is warranted after
transcatheter vaso-occlusion of PAVMs due to frequent recanalization of treated PAVMs
and development or growth of untreated PAVMs.
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More difficult are the treatment considerations for patients with diffuse PAVMs.
Lung transplantation has been tried unsuccessfully (unpublished), with no long-term
outcome data available to date. Redistribution of pulmonary blood flow, by occluding the
segmental arteries of an entire lobe has been used successfully and with improvement in
oxygenation. Unfortunately, a late complication, such as hemoptysis due to bronchial
artery hypertrophy has made this approach not ideal. One of the goals of this report is to
propose a new treatment approach, which we hope will improve oxygenation and
decrease the rate of hemoptysis in this subset of patients.

STATEMENT OF PURPOSE AND HYPOTHESIS
A small subset of patients with PAVMs has a more severe and diffuse pattern of
disease. These patients have a greater predisposition to neurological complications
compared to patients with focal PAVMs, and are more difficult to treat.
Before 2000, little was known about the clinical characteristics, course and
management of this subset of patients. In 2000, Faughnan et al defined diffuse PAVMs
and described the natural history of 16 patients with this subset of PAVMs (69). Since
then, little investigation has been done in this field.
The purpose of our study was multi-faceted:
1. To further describe the natural history of patients with diffuse PAVMs
2. To perform a review of the English-language literature on diffuse PAVMs,
focusing on how this subset has been defined to date
3. To develop a new anatomical classification of diffuse PAVMs and describe a new
treatment approach.
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We hypothesize that the lung of patients with diffuse PAVMs is focally diffuse,
such that some areas of an affected lobe are more diffuse than others. For example, the
right lower lobe has 5 bronchopulmonary artery segments. If 2 of 5 are diffusely
involved, then perhaps occluding these 2 more severely affected segments from
peripheral to central might show effective palliation (i.e. raise room air oxygenation of
the patient). Developing a new classification of the lung in patients with diffuse PAVMs
would aid in assessing whether occlusion of lung sub-segments with the most diffuse
involvement improves their oxygenation.

SUBJECTS AND METHODS
Literature Review
Case reports and reviews of patients with diffuse PAVMs were searched using
Medline and PubMed databases. Old reports that were not present in online databases
were identified by examining article references. Only reports in which diffuse PAVMs
were diagnosed by angiography or CT scan were considered to be properly classified as
diffuse. We believe that the diagnosis of diffuse PAVMS cannot be made correctly by
examining pathological specimens, so those reports were excluded.

Subject Selection, Demographics and Clinical Characteristics
36 patients with diffuse PAVMs were included in this study, from a cohort of 821
consecutive patients seen by Robert I. White, Jr. between May 1978 and December 2006.
15 of the 16 patients with diffuse PAVMs originally reported in the 2000 paper by
Faughnan et al were followed in this study. The rest of our cohort consisted of the
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additional 21 patients seen at the Yale Vascular Malformation Center or at the University
of Bari HHT Center. A retrospective review of medical records and images was
performed, after obtaining informed consents and an IRB approval. The following data
were collected:
•

HHT status - the diagnosis of HHT was made according to the Curaçao criteria, as
presented by Shovlin et al (18)

•

Gender

•

Age at presentation

•

Presence or absence of large focal PAVMs (≥ 3mm diameter artery)

•

Degree of diffuse involvement - all patients underwent diagnostic pulmonary
angiography, including measurements of pulmonary artery pressures; patients
were divided into 2 categories based on unilateral or bilateral lung involvement by
diffuse PAVMs, as well as the extent of each lung involvement as > or < than
50%

•

Oxygen saturations

•

Complications
o of the disease - brain abscess, TIA/stroke
o of embolotherapy- pleurisy, angina, coil migration
It is still unclear whether hemoptysis is a part of the disease itself, or a
complication of embolotherapy; regardless, it was included in this study as an
important complication.

•

Years of follow-up - calculated from the date of first visit to the date of last visit
or death
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•

Survival

Definition of Diffuse PAVM
Faughnan et al defined diffuse PAVM as involving all segmental branches of one
lobe (18). We believe that one lobe can be involved to different degrees, not necessarily
involving all the branches. Therefore, we felt that a more precise classification of the
diffuse subset of PAVMs was necessary. In our study, involvement was defined as
diffuse is at least 1 out of the 18 lung segments was diffusely affected (Figures 4 and 5).
Furthermore, if more than 5 out of 10 right lobe segments, or 4 out of 8 left lobe
segments were affected, the extent of involvement was considered more than 50%.
Unlike the patients with multiple focal PAVMs (Figure 6), involving one or more
segmental arteries, which are successfully treated with transcatheter embolotherapy
(TCE), response to treatment in patients with diffuse PAVMs is less satisfactory, with a
minimal rise in oxygen saturation after TCE. It is therefore important to distinguish
between multifocal (i.e. multiple focal) and diffuse PAVMs, which is often uncertain
until a post-occlusion angiogram is obtained.

Transcatheter Embolotherapy
The technique of embolotherapy performed at the Yale Vascular Malformation
Center has evolved in the past decade, as the increased frequency of hemoptysis from
bronchial arterial hypertrophy has been noted. The enlargement of bronchial arteries and
collateral filling of distal pulmonary arteries are likely a consequence of occlusion of
bronchial arteries by the central approach. Therefore, the technique was empirically
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changed from central to peripheral, blocking only the most severely affected segments
from distal to proximal with tightly packed fibered coils. This peripheral approach is
expected to exclude the diffusely involved segmental arteries from the pulmonary
circulation, thus redistributing the pulmonary blood flow to less involved or unaffected
segments of the lung. All patients were heparinized during embolotherapy because of a
thrombophlebitis in a previously reported patient (69).

Statistical Analysis
T-tests (continuous data) and chi-square (categorical data) analyses were used for
comparing subjects with unilateral versus bilateral disease. Patient data were entered in
an ACCESS database and imported in Statistical Analysis Software (SAS, Version 9.1;
Cary NC, 2005). Means, standard deviations and percentages were used to describe the
subjects.

RESULTS
Literature Review
About 5% of patients with HHT have a more severe and diffuse pattern of lung
involvement, however, little is known about the clinical characteristics, course and
management of these patients. A single attempt to assess the natural history and
appropriate management of these patients has been made to date (69). The rest are case
reports (73-95). From 1950 to 2007, over 50 patients have been reported as having
diffuse PAVMs (also described as “multiple microscopic fistulae”, “dispersed
telangiectasia”, “diffuse pulmonary telangiectasia”), excluding our cohort, and those with
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hepatopulmonary syndrome. In addition, at least 10 more diffuse cases from foreignlanguage publications were identified through English-language reviews or author’s
translations in PubMed. Out of all these cases, only a minority used appropriate
diagnostic tools (many inappropriately diagnosed diffuse PAVMs from pathology
specimens; others were in fact multifocal rather than diffuse), and matched our definition
of diffuse PAVMs.
Prior to the modern era, two papers defined diffuse PAVMs- Higgins and Currarino
(76, 96), both in 1976 as “pulmonary telangiectasia, in which innumerable minute
pulmonary arteriovenous fistulae between peripheral branches of the pulmonary arteries
and veins are distributed diffusely throughout both lings”. In 2000, Faughnan et al
redefined the diffuse subset as “AVMs involving every subsegmental artery of at least
one lobe” (69). Since 2000, very little has been published on patients with diffuse
PAVMs.
The majority of patients with diffuse PAVMs have HHT, generally present with
severe cyanosis and exercise intolerance, and appear to have a poor prognosis. Since
occlusion or resection of all AVMs in these patients is not a realistic treatment approach,
most of the reported patients have gone untreated. Prior to Faughnan’s study, little was
known about the risk of hemorrhagic and neurological complications in these patients.
Faughnan demonstrated that neurological rather than pulmonary complications are the
rule in this patient population. The incidence of neurological complications is higher in
patients with diffuse than in those with discrete PAVMs, such that brain abscesses have a
prevalence of 38% (69), as opposed to 9% in those with discrete PAVMs (60). This is not
surprising, since diffuse involvement may include hundreds of AVMs. Embolization of
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PAVMs in these patients does not improve the hypoxemia (as many untreated PAVMs
remain), but may reduce the risk of neurological sequelae. Therefore, these patients have
a fairly good prognosis with appropriate management, which should include
embolotherapy of larger AVMs, and life-long antibiotic prophylaxis for bacteremic
procedures.
In terms of pulmonary complications, these patients don’t tend to develop
spontaneous hemothorax, but can develop hemoptysis, often secondary to bronchial
artery hypertrophy (69). It is not known whether this hypertrophy is part of the disease
process or whether it develops subsequent to TCE. In terms of daily functioning, these
patients lead fairly normal lives, adapting to chronic hypoxemia by mainly unknown
mechanisms. Polycythemia, which likely helps compensate for hypoxemia, is present in
the majority of these patients. Pulmonary artery pressures are normal or decreased, likely
because of decreased pulmonary vascular resistance secondary to the diffuse AVMs.
Some might expect development of pulmonary hypertension in these patients, secondary
to chronic hypoxia. However, since hypoxic vasoconstriction occurs secondary to
alveolar hypoxia (which is not present in these patients) rather than hypoxemia, these
patients generally do not develop pulmonary hypertension.
When confronted with a patient with diffuse pulmonary AVMs, a clinician might
incorrectly presume a poor prognosis and suggest referral for lung transplantation (74).
However, the 2-year survival rate in the group presented by Faughnan et al that was
treated with TCE (91%) was better than that seen after lung transplantation (70%) (97).
Therefore, referral for lung transplantation has so far not been justified.
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Multi-Center Diffuse PAVM Series

General Characteristics

Since 2000, when we reported 16 patients with diffuse PAVMs, we have now
extended our database with additional 21 patients, and followed 15 out of the 16
previously reported ones. These 36 patients (21 female, 15 male) were chosen out of 821
consecutive patients (4.4%) because of their diffuse PAVM involvement, with one or
more segmental pulmonary artery affected. Mean age at presentation was 35.4 ± 17.8
years, with a mean follow-up of 8.5 ± 6.1 years, and a range of 0.12 to 26 years. HHT
was present in 29/36 (81%), and the morphology of PAVMs was consistent with HHT
and different from the type seen in hepatopulmonary syndrome. (98). Nine out of 35
(25%) died during the follow-up period, all of which had bilateral involvement. No
deaths occurred in patients with unilateral involvement, and this difference is statistically
significant (p=0.03).

Unilateral Diffuse PAVM Patients (Tables 1 and 3)

Unilateral involvement was found in 10/36 patients (28%); 2 were female and 8
were male, 7 of them with HHT. Two of the 10 patients were seen prior to 1998 (69), and
their mean age of first visit was 21 ± 11 years (range 4 to 37) with mean follow-up time
of 5.7 ± 4.8 years (range 0.12 to 16). Three of the 10 patients (30%) had complications at
the time of their initial presentation, including brain abscess (2) and hemoptysis (1).
Since 1998, 3 patients have had significant complications, but have all recovered. All 10
patients have remained fully functional, working or attending school fulltime.
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Bilateral Diffuse PAVM Patients (Tables 2 and 4)

Bilateral involvement was found in 26/36 patients (72%); 19 were female, 7 were
male, and 22 of them had HHT. Thirteen of the 26 patients were seen prior to 1998 (69).
The mean age at time of first visit was 24.8 ± 17.9 years (range 0.5 to 71) with the mean
follow-up time of 9.6 ± 6.3 years (range 0.4 to 26 years). Nineteen of the 26 patients
(73%) had complications at the time of their initial visit, including a single brain abscess
(7), two brain abscesses (2), single TIA/stroke (9), two strokes (1). Of the 17 patients
living, 14 are working or attending school fulltime, and 3 are considered disabled.

Transcatheter Embolotherapy

Two of the 10 (20%) patients with unilateral diffuse PAVM and 17/26 (65%)
patients with bilateral diffuse PAVM involvement also had focal PAVM (p=0.02)
(Tables 3 and 4). In these patients, only involved arteries with a diameter ≥3mm were
occluded as close to the fistula (peripherally) as possible (72).

In the severely symptomatic patients, peripheral to central occlusion of diffusely
involved segments was performed using standard coil techniques (Figure 7) (99). Oxygen
saturation values for patients with unilateral and bilateral diffuse PAVMs were initially
87% ± 7% and 79% ± 8% (p=0.02), and most recently 95% ± 3% and 85% ± 7% (p
<0.0001), respectively (Tables 3 and 4).

Six of the 36 patients underwent angiography and measurements of pulmonary
pressures, but without TCE. Three of those had no rise of 10mm or more of PaO2 upon
temporary occlusion of lower lobe pulmonary arteries, and were therefore not considered
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to be candidates for embolization. The other three patients did not require TCE because
they were relatively asymptomatic.

Complications

None of the patients had pulmonary hypertension, although some had elevated
pulmonary artery and left atrial pressures secondary to liver disease.

Thirteen of the 30 patients that underwent TCE had early complications postembolization with full recovery, including self-limited pleurisy in 11/12 and transient
angina in 1/12 (most likely sue to introduction of air embolus during TCE). Coil
migration did not occur in any of our patients.

Hemoptysis

Six of the 36 patients developed hemoptysis sometime during their course: one with
unilateral and one with bilateral before treatment, and four late after treatment (Tables 1
and 2).

A. Hemoptysis in Patients with Unilateral Diffuse PAVM

Two patients with unilateral involvement developed hemoptysis- one before and
one after embolization. The first one (Patient 5) had a viral URI causing severe
hemoptysis, and was treated successfully by bronchial artery embolization. She continues
to be aggressively treated with antitussives to prevent recurrence secondary to hard
coughing. The second patient (Patient 8) has developed recurrent hemoptysis, either
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spontaneous or with URIs, after initial TCE treatment of 3 segments of the right lower
lobe.

B. Hemoptysis in Patients with Bilateral Diffuse PAVM

Hemoptysis was present in 4/26 patients. The first patient (Patient 12) developed
massive hemoptysis and was treated by bronchial artery embolization, but in 2003 and
2005 developed hemoptysis again and died (69, 100). The second one (Patient 14) had
not been treated (69). The third patient (Patient 18) had massive hemoptysis, was
evaluated at another institution, and underwent a successful partial right lower lobe
lobectomy without recurrence of hemoptysis in 8 years. The fourth patient (Patient 20)
had recurrent spontaneous as well as URI-induced hemoptysis related to hard coughing.
Diffuse telangiectases were demonstrated in this patient with bronchoscopy. His
hemoptysis spontaneously resolved after 1996, with no recurrence.

Mortality

None of the patients with unilateral diffuse involvement died during 27 years of
follow-up. Nine deaths occurred in the group of 26 patients with bilateral diffuse
involvement. Six of these deaths occurred during the interval follow-up, and were
secondary to brain abscess (Patient 13), brain hemorrhage (Patient 25), hemoptysis
(Patient 12), and three from liver complications (Patient 17, 19 and 27)- subacute liver
hemorrhage and biliary necrosis (2) and ammonia intoxication (1).
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The mean age at fist visit of patients who died was not significantly different from
those still living- 25 ± 16 years versus 24 ± 23 years (p=0.22). Neither were the oxygen
saturations- 78% ± 7% versus 82% ± 9% (p=0.18).

DISCUSSION
Pulmonary arteriovenous malformations can cause hypoxemia, pulmonary
hemorrhage, and serious neurological complications, such as stroke or brain abscess.
About 5% of patients with PAVMs have a more severe and diffuse pattern of disease.
Little was known about the clinical characteristics, course and management of these
patients prior to the study by Faughnan et al in 2000 (69). Before that only case reports
appeared in the literature (73-95). Faughnan et al studied the natural history of 16
patients with diffuse PAVMs, and concluded that these patients are at increased risk of
neurological complications, and that transcatheter embolotherapy does not significantly
improve their profound hypoxia, but may reduce the risk of neurological complications.
Since then, very little has been published about these patients. Because patients
with diffuse PAVMs are associated with significant morbidity and mortality, more
frequent monitoring is required(69). In addition, we observed that hemoptysis, which is
rarely seen in patients with focal PAVMs, is a frequent finding in patients with diffuse
PAVMs. This is consistent with the finding that diffuse involvement is associated with
more complications, but we also began to question our treatment approach as a possible
cause of hemoptysis. Since Faughnan’s paper, the Yale technique has empirically
changed from proximal to distal occlusion, treating only the most severely affected
segmental arteries, as opposed to occluding the entire lobe proximally, in hopes of
preventing bronchial artery hypertrophy and, hence, hemoptysis. The need to re-classify
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the anatomy of diffuse PAVMs was recognized in light of this necessity for a better
treatment approach.
We extended the observations from the 2000 paper to additional 21 patients with
diffuse PAVMs, and followed up on 15 out of the 16 previously reported patients (69).
Furthermore, we preformed an extensive literature review of diffuse PAVMs, searching
for other attempts to re-define the anatomy of diffuse PAVMs.

Definition of Diffuse PAVMs
Prior to the 2000 report, diffuse PAVMs were often called pulmonary telangiectases
or microscopic arteriovenous fistulae, and were vaguely described as innumerable
fistulae or “spidery” small vessels, distributed diffusely throughout both lungs.
Classification of PAVMs into focal, multiple and diffuse has been around for
decades (67, 96), but there have been no prior attempts to distinguish between various
degrees of involvement of the lung with diffuse PAVMs. In the 2000 report, diffuse
PAVMs were defined as affecting all segmental branches of one lobe (69). We observed
that many patients with diffusely involved segmental arteries did not necessarily have all
arteries of a single lobe affected- some were spared or much less involved. Therefore, we
feel that it is more accurate to report diffuse involvement with respect to segments rather
than lobes. We consider involvement as diffuse if at least 1 of the 18 lung segments is
diffusely affected. Patients with only a small number of segments diffusely involved (2 or
3) have a sustained rise in oxygen saturation after peripheral to central occlusion.
It is important to note that multifocal PAVMs may be difficult to distinguish from
diffuse ones, in fact, many of the PAVMs that were reported in previous studies as
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diffuse were actually multifocal. The difference is that multifocal PAVMs respond well
to TCE, such that their post-embolization pulmonary angiogram generally appears almost
normal, and their oxygen saturation rises significantly. This does not happen with diffuse
PAVMs, making them much more difficult to treat.

Natural history of Diffuse PAVMs
Patients with diffuse PAVMs have been found to present earlier in life, usually with
exercise intolerance and profound cyanosis and appear to have a poor prognosis.

Neurological Complications
In patients with HHT, neurological complications are more frequently related to
PAVM than to hemorrhagic cerebral AVM (101).
Traditionally, neurological events occur in about 30% of patients with focal
PAVMs (66). Stroke/TIA occur in 10-20% of these patients(102), whereas cerebral
abscesses have been found in about 10% (60, 102). It has been pretty well shown that
follow-up every 5 years is all that is necessary in these patients with focal PAVMs (72).
In the small subset of HHT patients with diffuse PAVMs, these events are more
common. Faughnan and colleagues reported the rates of 50% for stroke/TIA and 38% for
cerebral abscesses (69). In our study, in which we followed for additional 8 years fifteen
out of the sixteen patients from Faughnan’s cohort (69), 5 patients (30%) had a stroke or
TIA during the follow-up period, while brain abscess occurred in 2 patients (13%). In the
21 new patients that we followed from 1998-1996, strokes/TIAs occurred in 3 of them
(14%), and two abscesses occurred in each of the 2 patients. Because of the higher risk of
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neurological complications, among others, yearly follow-up is recommended in patients
with diffuse PAVMs.
Neurological manifestations generally result from: secondary polycythemia and
hyperviscosity due to chronic hypoxia from right to left shunting, communication
between the airways and pulmonary circulation during cough produces gas embolism and
hemoptysis, and paradoxical emboli that pass through PAVMs (74). In patients with
diffuse PAVMs, hypoxemia is more severe, leading to greater degree of polycythemia
and hyperviscosity. In addition, since more PAVMs are present, there is a greater loss of
capillary filter function. Therefore, an increased risk of neurological complications in
patients with diffuse PAVMs is not surprising.
Cerebral abscesses in HHT are frequently due to multiple anaerobic organisms and
predominate in supratentorial areas of the brain (103). They were found to follow dental
procedures in more than half the cases (69). In HHT, brain abscesses occur at a younger
age than in the general population and may relapse (102). One of the deaths that occurred
in our cohort was due to a brain abscess in a patient that did not seek medical attention in
time. Any patient with PAVMs should seek medical attention for headache lasting more
than 24 hours. In addition, due to the risk of infections, antibiotic prophylaxis prior to
potentially bacteremic procedures is recommended in all HHT patients with a positive
bubble study, including those without a visible PAVM on imaging.

Hemoptysis
Hemoptysis in patients with diffuse PAVMs has emerged as an important symptom
that requires further understanding. In our cohort, hemoptysis was associated with a URI
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in most cases. If treated appropriately with antitussives, it rarely becomes massive
(>100ml/day). As part of the hemoptysis work-up, bronchoscopy is performed to rule out
telangiectasia of the tracheal bronchial mucosa.
In a recent report by Brillet et al, about 40% of patients with previously treated
focal PAVMs were found to have enlarged bronchial arteries (104). In this group of
patients, the frequency of clinical events suggestive of lung infarction in the days or
months after embolotherapy and the frequency of CT features suggestive of sequelae of
lung infarction on CT angiograms were significantly higher than those observed in the
group of patients without abnormal enlargement of systemic arteries. This supports the
already suggested hypothesis that the treatment of focal PAVMs may induce ischemia,
which could trigger enlargement of bronchial arteries supplying the PAVMs. Another
hypothesis is that bronchial artery hypertrophy is a part of the HHT syndrome. We have
empirically changed our treatment from central to peripheral occlusion, in hopes of
avoiding bronchial artery enlargement and collateral filling of distal pulmonary arteries,
and thus hemoptysis. In those patients that do not respond well to antitussives and
progress to massive hemoptysis, the Yale center has been successful at controlling this
symptom by performing bronchial embolotherapy (69, 100).
Improved knowledge of the frequency of congenital and acquired systemic arterial
supply of PAVMs, as well as predictive factors for the latter situation, requires precise
mapping of systemic arteries before embolotherapy, which was not done in the above
mentioned study by Brillet et al. Future studies investigating the role of bronchial
embolotherapy are needed.
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Mortality
Patients with bilateral involvement have greater mortality than those with unilateral
involvement. Six deaths occurred in our series, and neither age nor oxygen saturations
were predictors of death. Three of the deaths were potentially preventable. One was due
to massive hemoptysis and delay in seeking medical attention. The second one was in a
patient with a history of brain abscess, who did not seek prompt medical attention for
headache, which turned out to be a second abscess 21 years after the first one. Any
patient with a PAVM should seek medical attention for headache lasting over 24 hours.
Finally an infant with diffuse bilateral involvement died of cerebral hemorrhage, most
likely secondary to an undiagnosed CAVM, further emphasizing the importance of
screening all HHT patients for CAVMs during initial work-up.
The remaining 3 patients died of liver complications, which likely occur due to
shunting of poorly oxygenated blood through multiple liver AVMs. Up to 80% of HHT
patients have liver shunts(4), which rarely cause symptoms due to high output failure
(54). In our patients, 2 developed “liver disintegration”, a syndrome of liver hemorrhage,
pain and elevated alkaline phosphatase (105). The last patient developed progressive
ammonia intoxication without acute symptoms. Presently, in the United States, the
United Network for Organ Sharing (UNOS) does not recognize HHT as an indication for
liver transplant.

Treatment of Diffuse PAVMs
Before 1980, surgical resection was the only method of treatment of PAVMs (106,
107), and it rarely still has a role in patients in whom right-to-left shunting persists after
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embolization of all feasible vessels (44), or if a patient has severe contrast allergy,
precluding angiography.
Transcatheter embolization therapy has been the preferred method of treatment since the
1980’s as it avoids major surgery, general anesthesia, and loss of pulmonary parenchyma
and is technically-successful in over 98% of cases (71).
In 2006, Pollak et al published their results regarding outcomes of TCE in 154
patients with focal PAVMs (72). They had about a 3% reperfusion rate for focal PAVMs,
which may occur due to recanalization of an embolized vessel, or growth of missed or
previously small accessory artery.
More difficult are the treatment considerations for patients with diffuse PAVMs.
Lung transplantation has been reported in only a small number of patients. One of
the patients from the 2000 cohort died in the lung transplant peri-operative period. There
have been 2 case reports to date of lung transplantation as a therapeutic option for
PAVMs unresponsive to other forms of treatment (108, 109). The first case reported was
a double lung transplant in a patient with diffuse PAVMs, severe hypoxemia and multiple
previous failed attempts of TCE (109). This patient had a satisfactory short-term
outcome, but no follow-up has been published. The second case was a patient with
bilateral multifocal PAVMs with a previous lobectomy and one AV fistula occlusion,
who at 3 years post-transplantation of the right lung was performing normal daily
activities with oxygen saturations of 99%, even during exercise. The potential for
recurrence of the disease in the donor organ is still unknown. Given the very small
number of lung transplant cases in patients with PAVMs who are unresponsive to other
forms of treatment, more long-term outcome data is needed. Because of this lack of data
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and because survival with disease is difficult to predict, we currently do not recommend
lung transplantation as a therapeutic approach to diffuse PAVMs.
Redistribution of pulmonary blood flow, by occluding the segmental arteries of an
entire lobe has been used successfully and with improvement in oxygenation.
Unfortunately, a late complication, such as hemoptysis due to bronchial artery
hypertrophy has made this approach not ideal. Consequently, the Yale technique has
changed empirically based on follow-up of patients since 2000, such that only those
segmental arteries with diffuse involvement are occluded peripherally, from distal to
proximal, with pushable fibered coils (99). Our primary indication for embolotherapy at
initial evaluation of patients with diffuse PAVMs remains the same- occluding all focal
PAVMs with arteries 3mm or larger (72). In our series, large focal PAVMs were more
commonly found in the bilateral group. Embolization of these arteries protects against
paradoxical embolization, but not necessarily against bacterial embolization. Therefore,
antibiotic prophylaxis remains necessary to cover potentially bacteremic procedures (72).
The new Yale treatment approach to diffuse PAVMs is performed only in very
symptomatic patients, such as those experiencing dyspnea and fatigue, in the absence of
anemia as the underlying cause. Interestingly, many of our patients are relatively
asymptomatic despite very low oxygen saturations, likely reflecting the absence of
pulmonary hypertension or airway issues.
Complications of embolization therapy include pleuritic chest pain, air embolism,
with angina and bradycardia caused by air in the coronary arteries, and device migration
(2, 68, 110). In experienced hands, complication rates as a result of embolotherapy are
low, except for hemoptysis, which may or may not be due to TCE.
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Pleuritic chest pain may develop in 10% of patients after embolization, usually
developing 2 to 4 days after the procedure, often self-limited, and usually resolving
within 1 to 2 days with simple analgesia or anti-inflammatories (2).
Device migration has a previously reported incidence of 1.2% (66), but its
incidence in experienced hands is lower (2, 68, 110), and did not occur in any of our
patients. Migration of balloons or coils to the hepatic artery, the internal iliac artery, the
femoral artery, the carotid artery and the left ventricle has been reported (68, 111-113).
None of the reported migrations has resulted in permanent disability, although about half
required some intervention, usually with an intravascular retrieval device or, rarely,
emergency surgery (71, 112, 113). Device migration may be due to misjudgment of
balloon location, use of a balloon or coil that is too small for the artery to be occluded,
suboptimal fluoroscopic visualization, or complex anatomy with difficult access (68).
Various techniques for fixing the coil position to prevent distal migration can be used in
PAVMs with large feeding arteries (111).
In our cohort, complications were overall less in the unilateral group and their
response to TCE was superior to that in patients with bilateral involvement.
As a result of a low, but significant risk of reperfusion after embolization, which
results in recurrent risk of paradoxical embolization, monitoring for PAVM growth after
treatment is necessary. With all the concern from radiation (114), we should be able to
assess growth and monitor by less invasive means. Exercise testing measuring oxygen
saturation might be a solution to this problem, and is currently being developed at Yale.
Assessment of bronchial artery hypertrophy as a result of embolization and as a possible
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cause for hemoptysis, is another important issue which will be studied in the near future
at the Yale HHT Center.

Recommendations
Because of the small number of patients reported with diffuse PAVMs, it is still
difficult to make concrete recommendations about their management. However, we
firmly recommend yearly follow-up, given the increased morbidity and mortality
associated with these patients.
Embolization of PAVMs in patients with diffuse PAVMs does not improve their
hypoxemia (as many untreated PAVMs remain), but may reduce the risk of neurological
sequelae. Therefore, these patients have a fairly good prognosis with appropriate
management, which should include embolotherapy of larger AVMs, and life-long
antibiotic prophylaxis for bacteremic procedures (Figure 8).
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FIGURES

Five Genotypes
Two Very Common (70-80%)
Endoglin (HHT 1)

*
ALK-1 (HHT 2)

*
SMAD 4 (HHT JP)
Lancet Feb. 2004

* Two more genes linked to HHT (HHT 3 and HHT 4)
Figure 1. HHT Genotypes.
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Screening and Management for Brain
AVM
Brain MRI in all patients, without and
with gadolinium enhancement

No CAVM

CAVM with nidus
less than 10 mm

CAVM with nidus
greater than 10 mm

Consider
treatment

Stop
Repeat MRI
every 5 years

Figure 2. Yale HHT Center Recommendations: Screening and Management of Cerebral
Arteriovenous Malformations.
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Screening and Management for PAVM
• Contrast echocardiogram
• Supine and erect pulse oximetry
Both negative

Either positive
Helical Chest CT Scan

Stop

No PAVMs

Tiny PAVMs, with
feeding arteries < 3 mm

PAVMs with feeding
arteries³ 3 mm

• Pulmonary angiography & embolization
• 6 month CT scan to confirm adequate occlusion

Lifelong antibiotic prophylaxis
Follow-up CT scan every 5 years to assess for PAVM growth or sooner
Šbefore pregnancy for women and possibly during adolescence*

Figure 3. Yale HHT Center Recommendations: Screening and Management of
Pulmonary Arteriovenous Malformations.

4A.
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4B.

Figure 4A-B. Left anterior oblique selective right pulmonary angiogram early and late
arterial images. A. Diffuse involvement of the posterior and medial segment arteries,
while the anterior and lateral segments are uninvolved. B. In the late arterial phase, early
venous drainage into the left atrium is seen from the diffusely involved posterior medial
segments.
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5A.

5B.

Figure 5A-B. Shallow anterior oblique views of super selective right pulmonary
angiograms in late arterial phase. In both A (anterior segment) and B (lateral segment),
diffuse involvement from each subsegmental branch is noted. At the end of each
subsegmental branch are tiny, almost “telangiectasia type” abnormalities. The pulmonary
veins from each of these segments are already opacified.
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6A.

6B.

6C.

6D.
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6E.

6F.

Figure 6A-F. Young patient with multifocal PAVM in right lung. Earlier in life surgical
resection of her right superior segment had been performed. A (anterior) and B (lateral)
right pulmonary angiograms are demonstrating small PAVMs distally in right lower lobe
and right middle lobe. In C and D, super selective pulmonary angiogram in anterior
segment of right lower lobe demonstrates multiple focal PAVMs with early venous
drainage. In E and F, super selective pulmonary angiogram with catheter beyond right
middle lobe and anterior segment of lower lobe demonstrates “normal” pulmonary artery
anatomy following distal occlusion of each small focal PAVM. No early veins are seen and
angiogram is almost normal in the post-occlusion angiogram.

7A.
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7B.

Figure 7A-B. Post-occlusion angiograms from patient in Figure 1 after peripheral
occlusion of most involved segments in right lower lobe (posterior, anterior and lateral),
demonstrating the new approach of occluding from distal to proximal, using “tightly”
packed coils
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Diffuse PAVM
Occlude Marco PAVM

See Yearly in Clinic
Follow with Exercise Testing

SPECIAL INSTRUCTIONS

Aggressively Treat
Cough

Head CT if Severe
Headache >24 hours

LifelongAntibiotic
Prophylaxis

Figure 8. Yale HHT Center Recommendations: Diffuse PAVM Management Algorithm.
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PT
1
2

HHT
N
Y

Table 1. PATIENTS WITH UNILATERAL DIFFUSE PAVM
1980-1998
1998-2006
Sex Age Stroke/TIA BA HEMO Stroke/TIA BA HEMO
M
33
Y
F
31
Y

3
4
5
6
7
8
9
10

Y
Y
Y
N
N
Y
Y
Y

M
M
F
M
M
M
M
M

22
37
10
23
25
7
4
7

Y
Y
Y
Y

Y/F
16
10
4
6
6
1
1
6
4
<1

PT=patient, N=no, Y=yes, Sex, F=female, M=male, Age= age in years at
presentation, BA=brain abscess, HEMO= hemoptysis, Y/F=years of continuous followup. Patients 1-2 reported in previous
paper. Patients 3-10 seen after 1998.
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PT
11
12
13
14
15
16
17
18
19
20
21
22
23

HHT
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N

Sex
F
F
M
F
F
M
F
F
F
M
F
M
F

Table 2. PATIENTS WITH BILATERAL DIFFUSE PAVM
1980-1998
1998-2006
Age Stroke/TIA BA HEMO Stroke/TIA BA
29
24
Y
Y
15
Y
Y
Y
14
Y
Y
39
Y
Y
6
Y
42
Y
Y
20
Y
Y
Y
17
Y
Y
20
Y
50
Y
Y
Y
23
0.8

24
25
26
27
28
29
30
31
32
33
34
35

Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

F
F
F
F
F
F
F
F
F
M
M
M

12
0.5
43
71
6
4
49
28
5
9
15
9

36

Y

F

31

Y

2

Y

1+1 spinal
abscess

HEMO
2

2
Y

Y/F
17
15*
17*
5*
14
5*
6*
9
22*
26
9
13
1.5*
3
0.4*
5
3*
4
8
9
7
5
1
16
4
10

N=no, Y=yes, Sex, F=female, M=male, Age= age in years at presentation, BA=brain abscess,
HEMO= hemoptysis, Y/F=years of continuous follow-up. Patients 11-23 reported in previous
paper. Patients 24-36 seen after 1998.
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Table 3. PATIENTS WITH UNILATERAL DIFFUSE PAVM: DISTRIBUTION AND
OXIMETRY
Focal
PAVM
Right
Left
O2 saturation
PT HHT Sex >50% <50% >50% <50% Unil Bilat Initial Current
1
N
M
Y
Y
85%
95%
2
Y
F
Y
82%
90%
3
4
5
6
7
8
9
10

Y
Y
Y
N
N
Y
Y
Y

M
M
F
M
M
M
M
M

Y
Y
Y
Y
Y
Y
Y
Y

Y

91%
88%
73%
92%
N/A
90%
92%
71%

99%
96%
82%
92%
N/A
93%
89%
71%*

PT=patient, Sex F=female, M=male, >50%=5 or more segments of right lung or 4 or
more segments of left lung diffusely involved, <50% less than 5 segments of right
lung or 4 or more segments of left lung diffusely involved, Unil=unilatera,
Bilat=bilateral, N/A=not available. Inital and current O2 saturations are values in
room air, usually standing when first seen by us, and current values up to December
2006. Patients 3-10 seen after 1998. *Patient 10 was subsequently treated at
another institution, with O2 saturation of 98% in May 2007.
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Table 4. PATIENTS WITH BIILATERAL DIFFUSE PAVM: DISTRIBUTION AND
OXIMETRY
Focal
Right
Left
PAVM
O2 saturation
PT HHT Sex >50% <50% >50% <50% Unil Bilat Initial Current
11 N
F
Y
Y
Y
87%
93%
12 Y
F
Y
Y
Y
71%
94%
13 Y
M
Y
Y
Y
71%
86%
14 Y
F
Y
Y
67%
N/A
15 Y
F
Y
Y
Y
85%
87%
16 Y
M
Y
Y
Y
82%
81%
17 Y
F
Y
Y
Y
84%
70%
18 Y
F
Y
Y
Y
82%
92%
19 Y
F
Y
Y
Y
86%
87%
20 Y
M
Y
Y
Y
79%
74%
21 Y
F
Y
Y
Y
84%
96%
22 N
M
Y
Y
91%
87%
23 N
F
Y
Y
Y
75%
N/A
24
25
26
27
28
29
30
31
32
33
34
35
36

Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

F
F
F
F
F
F
F
F
F
M
M
M
F

Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y

Y
Y
Y

Y
Y

Y
Y
Y
Y

Y
Y
Y
Y

Y

Y

Y
Y
Y
Y

Y
Y

82%
77%
78%
86%
74%
67%
87%
88%
60%
83%
86%
65%
83%

76%
77%
89%
90%
65%
73%
76%
82%
68%
70%
94%
73%
89%

PT=patient, Sex F=female, M=male, >50%=5 or more segments of right lung or 4 or
more segments of left lung diffusely involved, <50% less than 5 segments of right
lung or 4 or more segments of left lung diffusely involved, Unil=unilatera,
Bilat=bilateral, N/A=not available. Inital and current O2 saturations are values in
room air, usually standing when first seen by us, and current values up to December
2006. Patients 11-23 reported in previous paper. Patients 24-36 seen after 1998.
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